Physician profile
Deborah Oshields
NPI 1285644781
$2,523.36
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $200 · 2021: $615 · 2022: $894 · 2024: $22.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $612.93 | 2019-2022 | |
| Abbvie INC. | $318.46 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.23 | 2019-2024 | |
| Currax Pharmaceuticals LLC | $126.63 | 2019-2022 | |
| Duchesnay USA Incorporated | $113.83 | 2019 | |
| Allergan, INC. | $101.03 | 2019-2020 | |
| Pfizer INC. | $90.61 | 2019-2020 | |
| Exeltis, USA INC. | $85.72 | 2021-2022 | |
| Medtronic, INC. | $83.94 | 2022 | |
| Mayne Pharma Commercial LLC | $73.62 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $70.91 | 2019 | |
| Astellas Pharma US INC | $64.16 | 2019-2021 | |
| Amgen INC. | $63.50 | 2019-2021 | |
| Therapeuticsmd, INC. | $55.50 | 2020-2022 | |
| Amag Pharmaceuticals, INC. | $52.08 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $49.72 | 2021 | |
| Shield Therapeutics INC | $44.90 | 2022 | |
| Organon LLC | $44.47 | 2021-2022 | |
| Roche Diagnostics Corporation | $41.47 | 2019-2020 | |
| Bausch Health US, LLC | $41.17 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $36.08 | 2019-2020 | |
| Daiichi Sankyo INC. | $35.76 | 2019-2022 | |
| Urovant Sciences INC | $34.86 | 2021 | |
| Hologic Sales and Service, LLC | $26.91 | 2020-2021 | |
| Agile Therapeutics, INC. | $24.58 | 2021-2022 | |
| Myovant Sciences INC. | $18.81 | 2022 | |
| Vistapharm, INC. | $14.51 | 2021 | |
| Kvk-Tech, INC. | $14.47 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.86 | 2020 | |
| Becton, Dickinson and Company | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Oshields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.